Top

Published in:

01-04-2022 | Heart Failure | Original Article

Liver fibrosis index as a novel prognostic factor in patients with pulmonary arterial hypertension

Authors: Asuka Furukawa, Yuichi Tamura, Kenta Yamada, Hirohisa Taniguchi, Narutaka Ohashi, Teruo Okabe, Akio Kawamura

Published in: Heart and Vessels | Issue 4/2022

Abstract

Liver dysfunction is an important determinant of the prognosis of left heart failure patients. However, few studies have reported on cardiohepatic interactions in right heart failure patients, a condition that is an important prognostic factor in pulmonary arterial hypertension (PAH). This study aimed to evaluate the existence and extent of hepatic fibrosis and its contribution as a prognostic factor in PAH. This prospective study enrolled 60 consecutive patients with PAH in the International University of Health and Welfare Mita Hospital from June 2016 to December 2017. After the application of the exclusion criteria, 35 patients were assessed for hepatic fibrosis, using real-time tissue elastography, and for clinical deterioration. Sixteen healthy controls were also assessed for comparison. The liver fibrosis index (LFI) was significantly higher in PAH patients than in healthy controls (1.214 ± 0.047 vs. 0.911 ± 0.059, P < 0.001), suggesting that PAH patients exhibited mild liver fibrosis. However, patients with deterioration (vs. no deterioration) had significantly higher LFI values (1.507 ± 0.078 vs. 1.080 ± 0.034, P < 0.001), independent from other established liver function parameters. A receiver operating characteristic curve analysis identified that an LFI ≥ 1.275 indicated a significant probability of clinical deterioration (hazard ratio: 8.4 (95% CI 1.5–45.4, P = 0.012), independent from other known PAH prognostic factors. PAH patients may exhibit subclinical liver fibrosis associated with chronic right heart failure. The LFI can serve as both a non-invasive evaluation of liver fibrosis and a predictive marker for the deterioration of PAH patients.

Available only for authorised users

Tamura Y, Kumamaru H, Satoh T, Miyata H, Ogawa A, Tanabe N, Hatano M, Yao A, Abe K, Tsujino I, Fukuda K, Kimura H, Kuwana M, Matsubara H, Tatsumi K, Japan PH Registry (JAPHR) Network (2017) Effectiveness and outcome of pulmonary arterial hypertension-specific therapy in Japanese patients with pulmonary arterial hypertension. Circ J 82:275–282

Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M; ESC Scientific Document Group (2016) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. the joint task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (ESC) and the European respiratory society (ERS). Endorsed by: association for european paediatric and congenital cardiology (AEPC), international society for heart and lung transplantation (ISHLT). Eur Heart J 37:67–119CrossRef

Poelzl G, Auer J (2015) Cardiohepatic syndrome. Curr Heart Fail Rep 12:68–78CrossRef

Nikolaou M, Parissis J, Yilmaz MB, Seronde MF, Kivikko M, Laribi S, Paugam-Burtz C, Cai D, Pohjanjousi P, Laterre PF, Deye N, Poder P, Cohen-Solal A, Mebazaa A (2013) Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. Eur Heart J 34:742–749CrossRef

Ambrosy AP, Vaduganathan M, Huffman MD, Khan S, Kwasny MJ, Fought AJ, Maggioni AP, Swedberg K, Konstam MA, Zannad F, Gheorghiade M; EVEREST trial investigators (2012) Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial. Eur J Heart Fail 14:302–311CrossRef

Allen LA, Felker GM, Pocock S, McMurray JJ, Pfeffer MA, Swedberg K, Wang D, Yusuf S, Michelson EL, Granger CB; CHARM Investigators (2009) Liver function abnormalities and outcome in patients with chronic heart failure: data from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Eur J Heart Fail 11:170–177CrossRef

Batin P, Wickens M, McEntegart D, Fullwood L, Cowley AJ (1995) The importance of abnormalities of liver function tests in predicting mortality in chronic heart failure. Eur Heart J 16:1613–1618CrossRef

Poelzl G, Ess M, Mussner-Seeber C, Pachinger O, Frick M, Ulmer H (2012) Liver dysfunction in chronic heart failure: prevalence, characteristics and prognostic significance. Eur J Clin Invest 42:153–163CrossRef

Yang JA, Kato TS, Shulman BP, Takayama H, Farr M, Jorde UP, Mancini DM, Naka Y, Schulze PC (2012) Liver dysfunction as a predictor of outcomes in patients with advanced heart failure requiring ventricular assist device support : use of the Model of End-stage Liver Disease (MELD) and MELD eXcluding INR (MELD-XI) scoring system. J Heart Lung Transplant 31:601–610CrossRef

10.

Samsky MD, Patel CB, DeWald TA, Smith AD, Felker GM, Rogers JG, Hernandez AF (2013) Cardiohepatic interactions in heart failure: an overview and clinical implications. J Am Coll Cardiol 61:2397–2405CrossRef

11.

Yoshihisa A, Kimishima Y, Kiko T, Sato Y, Watanabe S, Kanno Y, Abe S, Miyata-Tatsumi M, Sato T, Suzuki S, Oikawa M, Kobayashi A, Yamaki T, Sugimoto K, Kunii H, Nakazato K, Suzuki H, Ishida T, Takeishi Y (2018) Liver fibrosis marker, 7S domain of collagen type IV, in patients with pre-capillary pulmonary hypertension. Int J Cardiol 258:269–274CrossRef

12.

Shiina T (2013) JSUM ultrasound elastography practice guidelines: basics and terminology. J Med Ultrason 40:309–323CrossRef

13.

Fujimoto K, Wada S, Oshita M, Kato M, Tonomura A, Mitake T (2007) Non-invasive evaluation of hepatic fibrosis in patients with chronic hepatitis C using elastography. MEDIX 10:24–27

14.

Fujimoto K, Kato M, Kubo M, Yada N, Shiina T, Ueshima K, Yamada Y, Ishida T, Azuma M, Yamasaki M, Yamamoto K, Hayashi N, Takehara T (2013) Novel image analysis method using ultrasound elastography for noninvasive evaluation of hepatic fibrosis in patients with chronic hepatitis C. Oncology 84:3–12CrossRef

15.

Yada N, Kudo M, Morikawa H, Fujimoto K, Kato M, Kawada N (2013) Assessment of liver fibrosis with real-time tissue elastography in chronic viral hepatitis. Oncology 84:13–20CrossRef

16.

Kudo M, Shiina T, Moriyasu F, Iijima H, Tateishi R, Yada N, Fujimoto K, Morikawa H, Hirooka M, Sumino Y (2001) Kumada T (2013) JSUM ultrasound elastography practice guidelines: liver. J Med Ultrason 40:325–357CrossRef

17.

Hirooka M, Koizumi Y, Hiasa Y, Abe M, Ikeda Y, Matsuura B, Onji M (2011) Hepatic elasticity in patients with ascites: evaluation with real-time tissue elastography. AJR Am J Roentgenol 196:W766-771CrossRef

18.

Coghlan JG, Channick R, Chin K, Di Scala L, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Gaine S (2018) Targeting the prostacyclin pathway with selexipag in patients with pulmonary arterial hypertension receiving double combination therapy: insights from the randomized controlled GRIPHON study. Am J Cardiovasc Drugs 18:37–47CrossRef

19.

Tatsumi C, Kudo M, Ueshima K, Kitai S, Ishikawa E, Yada N, Hagiwara S, Inoue T, Minami Y, Chung H, Maekawa K, Fujimoto K, Kato M, Tonomura A, Mitake T, Shiina T (2010) Non-invasive evaluation of hepatic fibrosis for type C chronic hepatitis. Intervirology 53(1):76–81CrossRef

20.

Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ (1994) Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19:1513–1520CrossRef

21.

Ichida F, Tsuji T, Omata M, Ichida T, Inoue K, Kamimura T, Yamada G, Hino K, Yokosuka O, Suzuki H (1996) New inuyama classification; new criteria for histological assessment of chronic hepatitis. Int Hepatol Commun 6:112–119 (22 Intervirology 53:76–81)CrossRef

22.

Giallourakis CC (2013) Liver complications in patients with congestive heart failure. Gastroenterol Hepatol (N Y) 9:244–246

23.

Gelow JM, Desai AS, Hochberg CP, Glickman JN, Givertz MM, Fang JC (2010) Clinical predictors of hepatic fibrosis in chronic advanced heart failure. Circ Heart Fail 3:59–64CrossRef

24.

Fujimoto Y, Urashima T, Shimura D, Ito R, Kawachi S, Kajimura I, Akaike T, Kusakari Y, Fujiwara M, Ogawa K, Goda N, Ida H, Minamisawa S (2016) Low cardiac output leads hepatic fibrosis in right heart failure model rats. PLoS ONE 11:e0148666CrossRef

25.

McLaughlin VV, Hoeper MM, Channick RN, Chin KM, Delcroix M, Gaine S, Ghofrani HA, Jansa P, Lang IM, Mehta S, Pulido T, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A, Tapson VF, Perchenet L, Preiss R, Verweij P, Rubin LJ, Galiè N (2018) Pulmonary arterial hypertension-related morbidity is prognostic for mortality. J Am Coll Cardiol 71:752–763CrossRef

26.

Bedossa P, Dargère D, Paradis V (2003) Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38:1449–1457CrossRef

Title: Liver fibrosis index as a novel prognostic factor in patients with pulmonary arterial hypertension
Authors: Asuka Furukawa
Yuichi Tamura
Kenta Yamada
Hirohisa Taniguchi
Narutaka Ohashi
Teruo Okabe
Akio Kawamura
Publication date: 01-04-2022
Publisher: Springer Japan
Keywords: Heart Failure
Hypertension
Arterial Hypertension
Arterial Hypertension
Published in: Heart and Vessels / Issue 4/2022
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI: https://doi.org/10.1007/s00380-021-01951-7

2024 ASCO Annual Meeting

Springer Medicine

Liver fibrosis index as a novel prognostic factor in patients with pulmonary arterial hypertension

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2022

Clinical impact of perioperative atrial fibrillation on long-term recurrence of malignancy

Safety evaluation of high-risk myocardial micro-biopsy in a swine model

Right bundle branch block and risk of cardiovascular mortality: the Ibaraki Prefectural Health Study

Association of Nephronophthisis 4 genetic variation with cardiorenal syndrome and cardiovascular events in Japanese general population: the Yamagata (Takahata) study

One-year results for Japanese patients in RANGER II SFA

Catheter-related thrombosis after cardiac surgery in patients with both central venous and pulmonary artery catheters inserted into the right internal jugular vein: a single-center, prospective, observational study